Bernd Hewing1, Edward A Fisher. 1. Division of Cardiology (Preventive Cardiology), Department of Medicine, New York University School of Medicine, New York, New York 10016, USA.
Abstract
PURPOSE OF REVIEW: Raising HDL cholesterol (HDL-C) has become an attractive therapeutic target to lower cardiovascular risk in addition to statins. Inhibition of the cholesteryl ester transfer protein (CETP), which mediates the transfer of cholesteryl esters from HDL to apolipoprotein B-containing particles, leads to a substantial increase in HDL-C levels. Various CETP inhibitors are currently being evaluated in phase II and phase III clinical trials. However, the beneficial effect of CETP inhibition on cardiovascular outcome remains to be established. RECENT FINDINGS: Torcetrapib, the first CETP inhibitor tested in a phase III clinical trial (ILLUMINATE), failed in 2006 because of an increase in all-cause mortality and cardiovascular events that subsequently were attributed to nonclass-related off-target effects (particularly increased blood pressure and low serum potassium) related to the stimulation of aldosterone production. Anacetrapib, another potent CETP inhibitor, raises HDL-C levels by approximately 138% and decreases LDL cholesterol (LDL-C) levels by approximately 40%, without the adverse off-targets effects of torcetrapib (DEFINE study). The CETP modulator dalcetrapib raises HDL-C levels by approximately 30% (with only minimal effect on LDL-C levels) and proved safety in the dal-VESSEL and dal-PLAQUE trials involving a total of nearly 600 patients. Evacetrapib, a relatively new CETP inhibitor, exhibited favorable changes in the lipid profile in a phase II study. SUMMARY: The two ongoing outcome trials, dal-OUTCOMES (dalcetrapib) and REVEAL (anacetrapib), will provide more conclusive answers for the concept of reducing cardiovascular risk by raising HDL-C with CETP inhibition.
PURPOSE OF REVIEW: Raising HDL cholesterol (HDL-C) has become an attractive therapeutic target to lower cardiovascular risk in addition to statins. Inhibition of the cholesteryl ester transfer protein (CETP), which mediates the transfer of cholesteryl esters from HDL to apolipoprotein B-containing particles, leads to a substantial increase in HDL-C levels. Various CETP inhibitors are currently being evaluated in phase II and phase III clinical trials. However, the beneficial effect of CETP inhibition on cardiovascular outcome remains to be established. RECENT FINDINGS:Torcetrapib, the first CETP inhibitor tested in a phase III clinical trial (ILLUMINATE), failed in 2006 because of an increase in all-cause mortality and cardiovascular events that subsequently were attributed to nonclass-related off-target effects (particularly increased blood pressure and low serum potassium) related to the stimulation of aldosterone production. Anacetrapib, another potent CETP inhibitor, raises HDL-C levels by approximately 138% and decreases LDL cholesterol (LDL-C) levels by approximately 40%, without the adverse off-targets effects of torcetrapib (DEFINE study). The CETP modulator dalcetrapib raises HDL-C levels by approximately 30% (with only minimal effect on LDL-C levels) and proved safety in the dal-VESSEL and dal-PLAQUE trials involving a total of nearly 600 patients. Evacetrapib, a relatively new CETP inhibitor, exhibited favorable changes in the lipid profile in a phase II study. SUMMARY: The two ongoing outcome trials, dal-OUTCOMES (dalcetrapib) and REVEAL (anacetrapib), will provide more conclusive answers for the concept of reducing cardiovascular risk by raising HDL-C with CETP inhibition.
Authors: Anke H E M Klerkx; Karim El Harchaoui; Wim A van der Steeg; S Matthijs Boekholdt; Erik S G Stroes; John J P Kastelein; Jan Albert Kuivenhoven Journal: Arterioscler Thromb Vasc Biol Date: 2006-01-26 Impact factor: 8.311
Authors: Philip Barter; Antonio M Gotto; John C LaRosa; Jaman Maroni; Michael Szarek; Scott M Grundy; John J P Kastelein; Vera Bittner; Jean-Charles Fruchart Journal: N Engl J Med Date: 2007-09-27 Impact factor: 91.245
Authors: Lukas E Spieker; Isabella Sudano; David Hürlimann; Peter G Lerch; Markus G Lang; Christian Binggeli; Roberto Corti; Frank Ruschitzka; Thomas F Lüscher; Georg Noll Journal: Circulation Date: 2002-03-26 Impact factor: 29.690
Authors: Branko Simic; Matthias Hermann; Sidney G Shaw; Laurent Bigler; Urs Stalder; Carola Dörries; Christian Besler; Thomas F Lüscher; Frank Ruschitzka Journal: Eur Heart J Date: 2011-09-14 Impact factor: 29.983
Authors: Laurent Yvan-Charvet; Fumihiko Matsuura; Nan Wang; Mark J Bamberger; Tu Nguyen; Franz Rinninger; Xian-Cheng Jiang; Charles L Shear; Alan R Tall Journal: Arterioscler Thromb Vasc Biol Date: 2007-02-22 Impact factor: 8.311
Authors: Philip J Barter; Mark Caulfield; Mats Eriksson; Scott M Grundy; John J P Kastelein; Michel Komajda; Jose Lopez-Sendon; Lori Mosca; Jean-Claude Tardif; David D Waters; Charles L Shear; James H Revkin; Kevin A Buhr; Marian R Fisher; Alan R Tall; Bryan Brewer Journal: N Engl J Med Date: 2007-11-05 Impact factor: 91.245
Authors: Stephen J Nicholls; E Murat Tuzcu; Danielle M Brennan; Jean-Claude Tardif; Steven E Nissen Journal: Circulation Date: 2008-11-24 Impact factor: 29.690
Authors: Bernd Hewing; Saj Parathath; Tessa Barrett; Wing Ki Kellie Chung; Yaritzy M Astudillo; Tadateru Hamada; Bhama Ramkhelawon; Thomas C Tallant; Mohamed Shaif S Yusufishaq; Joseph A Didonato; Ying Huang; Jennifer Buffa; Stela Z Berisha; Jonathan D Smith; Stanley L Hazen; Edward A Fisher Journal: Arterioscler Thromb Vasc Biol Date: 2014-01-09 Impact factor: 8.311
Authors: Roberto Martínez-Beamonte; María A Navarro; Sergio Acin; Natalia Guillén; Cristina Barranquero; Carmen Arnal; Joaquín Surra; Jesus Osada Journal: PLoS One Date: 2013-01-29 Impact factor: 3.240